インフルエンザ診断・治療の世界市場：将来予測 (2025年～2030年)

インフルエンザ診断・治療市場は、CAGR 7.50％で2025年の427億1,900万米ドルから2030年には613億4,200万米ドルに成長すると予測されます。

インフルエンザ診断・治療市場は、特に医療へのアクセスが限られている地域における、世界のインフルエンザの高い流行によって、今後5年間で大きな成長が見込まれています。製品の品質向上と製品ラインナップの拡充を目的とした主要な市場参入企業による研究開発投資の増加が、予測期間中（2024-2029年）の市場成長をさらに促進すると予測されます。特に高リスク集団の健康アウトカムの改善に重点が置かれていることが、市場の拡大を裏付けています。

主な成長要因

世界のインフルエンザの流行増加は、依然として市場成長の主な促進要因です。北米ではA型インフルエンザウイルスが主流で、成人のインフルエンザ関連入院の約80%を占めています。欧州やアジア太平洋などの地域でのインフルエンザ罹患率の増加も、市場需要に大きく寄与しています。効果的な診断・治療ソリューションの必要性は、発熱、のどの痛み、乾いた咳、筋肉痛などの症状を特徴とするこの病気の伝染性によって増幅され、高齢者、妊婦、乳幼児、免疫不全者などの脆弱な集団では重症化や死亡につながる可能性があります。

特に日本、イタリア、ドイツなどの国々における世界人口の高齢化は、市場の成長をさらに後押ししています。免疫力が低下している高齢者は、インフルエンザの診断や治療を強化する必要があり、専用のキットやサービスの需要が高まっています。これらの地域では医療システムが確立しており、高度な診断・治療ソリューションの採用を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場スナップショット

• 市場概要
• 市場の定義
• 分析範囲
• 市場セグメンテーション

第3章 ビジネス情勢

• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析
• 業界バリューチェーン分析
• 政策と規制
• 戦略的提言

第4章 技術展望

第5章 世界のインフルエンザ診断・治療市場：インフルエンザの種類別

• イントロダクション
• A型
• B型
• その他

第6章 世界のインフルエンザ診断・治療市場：提供内容別

• イントロダクション
• 診断
  • 迅速インフルエンザ診断検査
  • 迅速分子アッセイ
  • RT-PCRおよびNAAT
  • 免疫蛍光アッセイ
  • 在宅インフルエンザ検査キット
• 治療
  • 抗ウイルス薬
  • ワクチン
  • その他

第7章 世界のインフルエンザ診断・治療市場：年齢層別

• イントロダクション
• 0～14歳
• 15～64歳
• 65歳以上

第8章 世界のインフルエンザ診断・治療市場：投与方法別

• イントロダクション
• 経口
• 鼻腔内
• 注射

第9章 世界のインフルエンザ診断・治療市場：エンドユーザー別

• イントロダクション
• 病院・病院検査室
• 外来診療所
• 薬局・小売クリニック
• 参考検査室
• 在宅医療/自己検査ユーザー

第10章 世界のインフルエンザ診断・治療市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • インドネシア
  • タイ
  • その他

第10章 競合環境と分析

• 主要企業と戦略分析
• 市場シェア分析
• 企業合併・買収 (M&A)・合意・コラボレーション
• 競合ダッシュボード

第11章 企業プロファイル

• QuidelOrtho Corporation
• F. Hoffmann-La Roche AG
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• SA Scientific, Ltd.
• Sekisui Diagnostics, LLC
• Meridian Bioscience, Inc.
• Oxford Biosystems Ltd.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline plc
• Abbott Laboratories
• Danaher Corporation
• Sanofi S.A.
• Hologic, Inc.
• Luminex Corporation
• DiaSorin S.p.A.

第12章 付録

• 通貨
• 前提条件
• 基準年と予測年のタイムライン
• 利害関係者にとっての主なメリット
• 分析手法
• 略語

The Global Flu Diagnostic And Treatment Market is expected to grow from USD 42.719 billion in 2025 to USD 61.342 billion in 2030, at a CAGR of 7.50%.

The global flu diagnostic and treatment market is expected to experience significant growth over the next five years, driven by the high prevalence of influenza worldwide, particularly in regions with limited healthcare access. Rising investments in research and development by key market players to enhance product quality and expand offerings are anticipated to further propel market growth during the forecast period (2024-2029). The focus on improving health outcomes, especially for high-risk populations, underscores the market's expansion.

Key Growth Drivers

The increasing prevalence of influenza globally remains a primary driver of market growth. In North America, influenza A viruses dominate, accounting for approximately 80% of adult influenza-related hospitalizations. The growing incidence of flu in regions such as Europe and Asia Pacific also contributes significantly to market demand. The need for effective diagnostic and treatment solutions is amplified by the disease's contagious nature, characterized by symptoms like fever, sore throat, dry cough, and muscle pain, which can lead to severe illness or death in vulnerable groups, including the elderly, pregnant women, infants, and immunocompromised individuals.

The aging global population, particularly in countries like Japan, Italy, and Germany, further fuels market growth. Older adults, with weaker immune systems, require enhanced flu diagnostics and treatments, increasing demand for specialized kits and services. Well-established healthcare systems in these regions support the adoption of advanced diagnostic and treatment solutions.

Market Segmentation

By Flu Type

• The market is segmented into Type A and Type B influenza viruses. Type A dominates due to its higher prevalence and greater number of clinically diagnosed cases and hospitalizations compared to Type B. The Type A segment is expected to maintain a significant market share through 2029. While Type B flu has a lower incidence, its growing prevalence, particularly in the Asia Pacific region, is anticipated to drive modest growth in this segment over the forecast period.

By End-User

• The market is categorized into hospital laboratories, outpatient clinics, and reference laboratories. Outpatient clinics are projected to exhibit notable growth due to their cost-effective, point-of-care treatment offerings. Hospital laboratories, however, are expected to retain a significant market share, driven by their ability to provide long-term care and perceived reliability. Reference laboratories also contribute to the market but to a lesser extent.
• Geographical Outlook
• The Asia Pacific region is poised for robust growth, fueled by the rising prevalence of influenza in countries like India, China, and Indonesia, coupled with increasing healthcare expenditure in developing nations. North America is expected to maintain a substantial market share, supported by well-established healthcare systems in the U.S. and Canada and high healthcare spending. These factors collectively position North America and Asia Pacific as key regions driving the global flu diagnostic and treatment market through 2029.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
• What do businesses use our reports for?
• Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Global Flu Diagnostic and Treatment Market Segmentation:

By Type of Flu

• Type A
• Type B
• Others

By Offering

• Diagnostics
• Rapid Influenza Diagnostic Test
• Rapid Molecular Assay
• RT-PCR & NAATs
• Immunofluorescence Assays
• At-Home Flu Testing Kits
• Therapeutics
• Antiviral Medications
• Vaccines
• Others

By Age Group

• 0-14 Years
• 15-64 Years
• >=65 Years

By Mode of Administration

• Oral
• Intranasal
• Injectable

By End-User

• Hospitals & Hospital Laboratories
• Outpatient Clinic
• Pharmacies & Retail Clinics
• Reference Laboratories
• Home Care/Self-Test Users

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• UAE
• Other
• Asia Pacific
• China
• Japan
• South Korea
• India
• Thailand
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU

• 5.1. Introduction
• 5.2. Type A
• 5.3. Type B
• 5.4. Others

6. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Rapid Influenza Diagnostic Test
  • 6.2.2. Rapid Molecular Assay
  • 6.2.3. RT-PCR & NAATs
  • 6.2.4. Immunofluorescence Assays
  • 6.2.5. At-Home Flu Testing Kits
• 6.3. Therapeutics
  • 6.3.1. Antiviral Medications
  • 6.3.2. Vaccines
  • 6.3.3. Others

7. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP

• 7.1. Introduction
• 7.2. 0-14 Years
• 7.3. 15-64 Years
• 7.4. >=65 Years

8. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY MODE OF ADMINISTRATION

• 8.1. Introduction
• 8.2. Oral
• 8.3. Intranasal
• 8.4. Injectable

9. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER

• 9.1. Introduction
• 9.2. Hospitals & Hospital Laboratories
• 9.3. Outpatient Clinic
• 9.4. Pharmacies & Retail Clinics
• 9.5. Reference Laboratories
• 9.6. Home Care/Self-Test Users

10. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. USA
  • 10.2.2. Canada
  • 10.2.3. Mexico
• 10.3. South America
  • 10.3.1. Brazil
  • 10.3.2. Argentina
  • 10.3.3. Others
• 10.4. Europe
  • 10.4.1. Germany
  • 10.4.2. France
  • 10.4.3. United Kingdom
  • 10.4.4. Spain
  • 10.4.5. Others
• 10.5. Middle East and Africa
  • 10.5.1. Saudi Arabia
  • 10.5.2. UAE
  • 10.5.3. Others
• 10.6. Asia Pacific
  • 10.6.1. China
  • 10.6.2. India
  • 10.6.3. Japan
  • 10.6.4. South Korea
  • 10.6.5. Indonesia
  • 10.6.6. Thailand
  • 10.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. QuidelOrtho Corporation
• 11.2. F. Hoffmann-La Roche AG
• 11.3. Becton, Dickinson and Company
• 11.4. Thermo Fisher Scientific Inc.
• 11.5. SA Scientific, Ltd.
• 11.6. Sekisui Diagnostics, LLC
• 11.7. Meridian Bioscience, Inc.
• 11.8. Oxford Biosystems Ltd.
• 11.9. Pfizer Inc.
• 11.10. Bayer AG
• 11.11. GlaxoSmithKline plc
• 11.12. Abbott Laboratories
• 11.13. Danaher Corporation
• 11.14. Sanofi S.A.
• 11.15. Hologic, Inc.
• 11.16. Luminex Corporation
• 11.17. DiaSorin S.p.A.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations